Between October 6 and 8, 2026, the National Agency for the Safety of Medicines and Health Products (ANSM) reported changes in the availability of several medical products distributed through both pharmacies and hospitals, or only to hospitals. These updates come as part of ongoing efforts to manage supply chains and ensure that essential medications remain accessible to patients. Two specific products are currently facing challenges in their availability. FLUOROURACILE PFIZER 50 mg/mL solution to be diluted for infusion (fluorouracil), a medication used in the treatment of certain cancers, has resumed distribution in hospitals but only in limited quantities. The situation is described as being under "tension," meaning there is a shortage or restricted supply. Hospitals are receiving the drug based on a rationed distribution that meets their weekly needs. However, there is a delay in receiving the 20 mL vial of the drug, and emergency assistance from the laboratory Accord Healthcare has been activated to help manage the situation. The availability date for this product is now uncertain and will not be in 2026, as previously expected. Another product facing availability issues is MODAMIDE 5 mg tablet (amiloride), a medication used to treat high blood pressure and fluid retention. This drug is expected to remain under tension in the pharmacy sector until January 2027. The hospital supply of amiloride is not affected, but pharmacies are experiencing a shortage. As a result, there is a quantitative rationing in the city, meaning that only limited quantities are available to pharmacies. The expected availability date for this product is set to begin in January 2027. These supply issues highlight the challenges in maintaining a steady flow of essential medications and the need for continuous monitoring and management by health authorities. Patients and healthcare providers are advised to stay informed about any updates from the ANSM and to consult with their medical professionals for guidance on treatment options.